logo
Plus   Neg
Share
Email

Array BioPharma Enters Into Clinical Trial Collaboration Agreement With Pfizer

Array BioPharma Inc. (ARRY) said it has entered into a clinical trial collaboration agreement with Pfizer Inc. (PFE) to investigate the safety and efficacy of several novel anti-cancer combinations.

This includes Array's MEK inhibitor, binimetinib, with Pfizer's investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.

The two companies entered into this collaboration to explore the potential benefits of combining molecularly targeted therapeutics with the body's innate cancer-fighting abilities using immunotherapy.

Under the terms of the agreement, Array and Pfizer will collaborate on a Phase 1b clinical trial to explore a series of novel combinations, investigating the safety and efficacy of the combination of binimetinib, avelumab and talazoparib across various tumor types.

The companies expect a multi-arm clinical trial to establish recommended doses of different regimens combining the drugs. Initially the focus will be in non-small cell lung cancer or NSCLC and pancreatic cancer, and additional indications will be explored at a later stage.

The study is expected to begin by the third quarter of 2018, and results will be used to determine optimal approaches to further clinical development of these combinations.

Under the collaboration agreement, the trial will be sponsored and funded by Pfizer, with Array providing binimetinib supply.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Hundreds of Google employees signed a petition protesting the company's secret project to develop a censored version of its search engine for China. In a letter, posted by Buzzfeed and first reported by the New York Times, the employees said that work on the project and Google's return to China raises "urgent moral and ethical issues." Google is trying to keep a foothold in China. U.S. President Donald Trump has expressed support for a possible end to quarterly earnings reports for publicly traded companies, saying it would allow greater flexibility and save money. Nvidia Corp. (NVDA) Thursday reported a surge in its second-quarter profit, driven largely by a better-than-expected growth in revenues and strong margins. However, shares of the graphics chip maker slipped about 4 percent in extended session, as its revenue outlook for the current quarter fell short...
Follow RTT